99 related articles for article (PubMed ID: 10927148)
1. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.
Shibamoto Y; Kubota T; Kishii K; Tsujitani M
Radiother Oncol; 2000 Aug; 56(2):265-70. PubMed ID: 10927148
[TBL] [Abstract][Full Text] [Related]
2. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo.
Yahiro T; Masui S; Kubota N; Yamada K; Kobayashi A; Kishii K
J Radiat Res; 2005 Sep; 46(3):363-72. PubMed ID: 16210793
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas.
Matsuoka H; Shibamoto Y; Kubota T; Tsujitani M; Majima T
Oncol Rep; 2000; 7(1):23-6. PubMed ID: 10601585
[TBL] [Abstract][Full Text] [Related]
4. Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells.
Aoki M; Furusawa Y; Shibamoto Y; Kobayashi A; Tsujitani M
J Radiat Res; 2002 Jun; 43(2):161-6. PubMed ID: 12238330
[TBL] [Abstract][Full Text] [Related]
5. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption.
Yasui H; Asanuma T; Kino J; Yamamori T; Meike S; Nagane M; Kubota N; Kuwabara M; Inanami O
BMC Cancer; 2013 Mar; 13():106. PubMed ID: 23496909
[TBL] [Abstract][Full Text] [Related]
6. A nitroimidazole derivative, PR-350, enhances the killing of pancreatic cancer cells exposed to high-dose irradiation under hypoxia.
Mizumoto K; Qian LW; Zhang L; Nagai E; Kura S; Tanaka M
J Radiat Res; 2002 Mar; 43(1):43-51. PubMed ID: 12056329
[TBL] [Abstract][Full Text] [Related]
7. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.
Murata R; Tsujitani M; Horsman MR
Radiother Oncol; 2008 Jun; 87(3):331-8. PubMed ID: 18375007
[TBL] [Abstract][Full Text] [Related]
8. Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity.
Bi YL; Min M; Shen W; Liu Y
Tumour Biol; 2016 Nov; 37(11):15145-15155. PubMed ID: 27677287
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study.
Karasawa K; Sunamura M; Okamoto A; Nemoto K; Matsuno S; Nishimura Y; Shibamoto Y
Radiother Oncol; 2008 Jun; 87(3):326-30. PubMed ID: 18342968
[TBL] [Abstract][Full Text] [Related]
10. Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy.
Nemoto K; Shibamoto Y; Ohmagari J; Baba Y; Ebe K; Ariga H; Takai Y; Ouchi A; Sasai K; Shinozaki M; Tsujitani M; Sakaguchi M; Yamada S; Sakamoto K
Anticancer Drugs; 2001 Jan; 12(1):1-6. PubMed ID: 11272282
[TBL] [Abstract][Full Text] [Related]
11. The radiosensitizing effect of doranidazole on human colorectal cancer cells exposed to high doses of irradiation.
Zhang L; Gong A; Ji J; Wu Y; Zhu X; Lv S; Lv H; Sun X
BMC Cancer; 2007 Oct; 7():188. PubMed ID: 17919337
[TBL] [Abstract][Full Text] [Related]
12. Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350).
Kuwabara M; Iida Y; Inanami O; Sawamura S; Yokoyama K; Tsujitani M
J Radiat Res; 2002 Mar; 43(1):77-88. PubMed ID: 12056332
[TBL] [Abstract][Full Text] [Related]
13. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.
Mohiuddin M; Chendil D; Dey S; Alcock RA; Regine W; Mohiuddin M; Ahmed MM
Anticancer Res; 2002; 22(2A):825-30. PubMed ID: 12014658
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitization by a new potent nucleoside analog: 1-(1',3',4'-trihydroxy-2'-butoxy)methyl-2-nitroimidazole(RP-343).
Murayama C; Suzuki A; Sato C; Tanabe Y; Shoji T; Miyata Y; Nishio A; Suzuki T; Sakaguchi M; Mori T
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):433-43. PubMed ID: 8514541
[TBL] [Abstract][Full Text] [Related]
15. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity.
Oya N; Shibamoto Y; Sasai K; Shibata T; Murata R; Takagi T; Iwai H; Suzuki T; Abe M
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):119-27. PubMed ID: 7642409
[TBL] [Abstract][Full Text] [Related]
16. Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole
Yasui H; Kubota N; Nishizumi J; Sakai Y; Yamamori T; Inanami O
Oncol Lett; 2018 Feb; 15(2):1993-1998. PubMed ID: 29434899
[TBL] [Abstract][Full Text] [Related]
17. MGDG extracted from spinach enhances the cytotoxicity of radiation in pancreatic cancer cells.
Akasaka H; Mizushina Y; Yoshida K; Ejima Y; Mukumoto N; Wang T; Inubushi S; Nakayama M; Wakahara Y; Sasaki R
Radiat Oncol; 2016 Nov; 11(1):153. PubMed ID: 27876069
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay.
Shibamoto Y; Streffer C; Sasai K; Oya N; Abe M
Int J Radiat Biol; 1992 Apr; 61(4):473-8. PubMed ID: 1349329
[TBL] [Abstract][Full Text] [Related]
19. Type I interferons as radiosensitisers for pancreatic cancer.
Morak MJ; van Koetsveld PM; Kanaar R; Hofland LJ; van Eijck CH
Eur J Cancer; 2011 Sep; 47(13):1938-45. PubMed ID: 21478011
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
